Provisional guideline recommendation for EGFR gene mutation testing in liquid samples of lung cancer patients: A proposal by the Korean Cardiopulmonary Pathology Study Group

Korean Cardiopulmonary Pathology Study Group

Research output: Contribution to journalReview article

1 Scopus citations


Liquid biopsy for detection of mutation from circulating tumor DNA is a new technology which is attractive in that it is non-invasive. Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) is an effective first line drug for advanced non-small cell lung cancer patients who harbor activating EGFR mutation. During the course of treatment, resistance against TKI arises which can be contributed to EGFR T790M mutation in about 50–60% of patients. Third generation TKI may overcome the resistance. In patients who cannot undergo tissue biopsy due to variable reasons, liquid biopsy is an excellent alternative for the detection of EGFR T790M mutation. However, this relatively novel method requires standardization and vigorous quality insurance. Thus, a standard set of guideline recommendations for liquid biopsy for EGFR mutation testing suitable for the Korean medical community is necessary. In this article, we propose a set of provisional guideline recommendations that was discussed and approved by the Cardiopulmonary Pathology Study Group of the Korean Society of Pathologists.

Original languageEnglish
Pages (from-to)153-158
Number of pages6
JournalJournal of Pathology and Translational Medicine
Issue number3
StatePublished - 1 May 2019
Externally publishedYes



  • Carcinoma, non-small-cell lung
  • Circulating tumor DNA
  • Epidermal growth factor receptor
  • Liquid biopsy
  • T790M

Cite this